We've heard how the use of drugs like Ozempic can drive weight loss, as well as potentially boost heart health and cut out ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Consumers may cycle on and off GLP-1 medications because of financial constraints. These consumers present opportunities for ...

FROM sulphur burps to diarrhoea, we’re all familiar with the brutal side effects of fat jabs – but have you heard of ‘Ozempic ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

A new Canadian guideline urges lifestyle interventions for obese children but also says today's new drugs might help kids ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...